Literature DB >> 21085091

Syringe exchange programs --- United States, 2008.

.   

Abstract

Persons who inject drugs should use a new, sterile needle and syringe for each injection. Syringe exchange programs (SEPs) provide free sterile syringes and collect used syringes from injection-drug users (IDUs) to reduce transmission of bloodborne pathogens, including human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus (HCV). As of March 2009, a total of 184 SEPs were known to be operating in 36 states, the District of Columbia (DC), and Puerto Rico (North American Syringe Exchange Network [NASEN], unpublished data, 2009). Of these, 123 (67%) SEP directors participated in a mail/telephone survey conducted by NASEN and Beth Israel Medical Center (New York, New York) that covered program operations for the calendar year 2008. To characterize SEPs in the United States, this report summarizes the findings from that survey and compares them with previous SEP survey results from the period 1994-2007. In 2008, the 123 SEPs reported exchanging 29.1 million syringes and had budgets totaling $21.3 million, of which 79% came from state and local governments. Most of the SEPs reported offering preventive health and clinical services in addition to basic syringe exchange: 87% offered HIV counseling and testing, 65% offered hepatitis C counseling and testing, 55% offered sexually transmitted disease screening, and 31% offered tuberculosis screening; 89% provided referrals to substance abuse treatment. Providing comprehensive prevention services and referrals to IDUs, such as those offered by many SEPs, can help reduce the spread of bloodborne infections and should increase access to health care and substance abuse treatment, thus serving as an effective public health approach for this population.

Entities:  

Mesh:

Year:  2010        PMID: 21085091

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  19 in total

1.  Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment.

Authors:  Aaron D Fox; Adam Chamberlain; Taeko Frost; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2015       Impact factor: 3.716

2.  Demographic, risk, and spatial factors associated with over-the-counter syringe purchase among injection drug users.

Authors:  Thomas J Stopka; Alexandra Lutnick; Lynn D Wenger; Kathryn Deriemer; Estella M Geraghty; Alex H Kral
Journal:  Am J Epidemiol       Date:  2012-05-04       Impact factor: 4.897

3.  Integrating health and prevention services in syringe access programs: a strategy to address unmet needs in a high-risk population.

Authors:  Carolyn K Burr; Deborah S Storm; Mary Jo Hoyt; Loretta Dutton; Linda Berezny; Virginia Allread; Sindy Paul
Journal:  Public Health Rep       Date:  2014 Jan-Feb       Impact factor: 2.792

4.  Conceptual framework for behavioral and social science in HIV vaccine clinical research.

Authors:  Chuen-Yen Lau; Edith M Swann; Sagri Singh; Zuhayr Kafaar; Helen I Meissner; James P Stansbury
Journal:  Vaccine       Date:  2011-08-05       Impact factor: 3.641

5.  Using Pharmacies in a Structural Intervention to Distribute Low Dead Space Syringes to Reduce HIV and HCV Transmission in People Who Inject Drugs.

Authors:  Christine U Oramasionwu; Terence L Johnson; William A Zule; Jessica Carda-Auten; Carol E Golin
Journal:  Am J Public Health       Date:  2015-04-16       Impact factor: 9.308

6.  Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: A pilot study.

Authors:  B L Norton; M A Bachhuber; R Singh; L Agyemang; J H Arnsten; C O Cunningham; A H Litwin
Journal:  Int J Drug Policy       Date:  2019-04-16

7.  Differences in HIV risk behavior of injection drug users in New York City by health care setting.

Authors:  A K Turner; K Harripersaud; N D Crawford; A V Rivera; C M Fuller
Journal:  AIDS Care       Date:  2013-03-01

8.  Feasibility of providing interventions for injection drug users in pharmacy settings: a case study among San Francisco pharmacists.

Authors:  Valerie J Rose; Alexandra Lutnick; Alex H Kral
Journal:  J Psychoactive Drugs       Date:  2014 Jul-Aug

Review 9.  Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs.

Authors:  Kinna Thakarar; Katherine Nenninger; Wollelaw Agmas
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

10.  Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.

Authors:  Charitha Gowda; Vincent Lo Re
Journal:  Curr Hepatol Rep       Date:  2018-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.